Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized prospective single center study.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Jan 2012

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meropenem (Primary)
Indications Bacterial infections
Focus Therapeutic Use

Most Recent Events

22 Jan 2012 Additional trial identifier (26147641), trial centre and investigator identified and inclusion, exclusion criteria added as reported by ISRCTN: Current Controlled Trials.
21 Jan 2012 Actual end date (Apr 2010) added as reported by ISRCTN: Current Controlled Trials
21 Jan 2012 Actual initiation date (Oct 2007) added as reported by ISRCTN: Current Controlled Trials.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight